Al Prediction of Sarcopenia Risk in Neurocritical ICU Patients

NCT07712198 | Completed

• 1 other identifier: 10496660-2026-25030
• Study Type: observational
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective observational study aims to evaluate sarcopenia in intensive care patients with intracranial pathologies using ultrasound and to compare the predictive performance of different artificial intelligence models. Rectus femoris muscle thickness will be measured by ultrasound on ICU admission (Day 0) and Day 7. Prealbumin levels will be assessed on Days 0, 3, and 7, and the modified Nutrition Risk in Critically Ill (mNUTRIC) score will be calculated on the first day of ICU admission. Clinical, laboratory, and ultrasonographic data will be integrated into different artificial intelligence models to predict sarcopenia status on Day 7. The study aims to determine the effectiveness of artificial intelligence in the early identification of sarcopenia and to support future clinical decision-making in intensive care practice.

Conditions

Ischemic Stroke; Brain Neoplasms; Intracerebral Hemorrhage; Subarachnoid Hemorrhage; Subdural Hematoma; Epidural Hematoma

Keywords

Sarcopenia; Artificial Intelligence; Intensive Care Unit; Rectus Femoris; Ultrasonography; mNUTRIC; Prealbumin; Intracranial Pathology

Outcome Measures

Primary Outcomes (1)

• Accuracy of Artificial Intelligence Models in Predicting Day-7 Sarcopenia

  Evaluation of the predictive performance of ChatGPT, Gemini, and Claude models for day-7 sarcopenia in ICU patients with intracranial pathology using rectus femoris muscle thickness, prealbumin levels, and clinical data.

  7 Days

Secondary Outcomes (2)

• Comparison of Predictive Performance Among AI Models

  7 Days

• Agreement Between AI Predictions and Clinical Assessment

  7 Days

Study Arms (1)

Intracranial Pathology ICU Patients

Adult patients admitted to the intensive care unit with intracranial pathologies, including intracerebral hemorrhage, subarachnoid hemorrhage, subdural hematoma, epidural hematoma, intracranial tumors, and ischemic stroke. Participants will be prospectively observed. Rectus femoris muscle thickness will be measured by ultrasonography on days 0 and 7, and prealbumin levels will be assessed on days 0, 3, and 7. No experimental intervention or treatment modification will be performed.

Other: Prospective Observational Assessment

Interventions

Prospective Observational Assessment OTHER

Prospective observational assessment including rectus femoris ultrasonography, prealbumin measurements, mNUTRIC scoring, and collection of routine clinical data. No experimental intervention or treatment modification will be performed.

Intracranial Pathology ICU Patients

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult intensive care unit patients aged 18-65 years admitted with intracranial pathologies, including intracerebral hemorrhage, epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, intracranial tumors, and ischemic stroke.

You may qualify if:

• Age between 18 and 65 years
• Admission to the intensive care unit due to intracranial pathology (intracerebral hemorrhage, epidural hemorrhage, subdural hemorrhage, subarachnoid hemorrhage, intracranial tumors, or ischemic stroke)
• Informed consent obtained from the patient or legally authorized representative

You may not qualify if:

• Age \<18 years or \>65 years
• Failure to achieve nutritional targets according to ESPEN guidelines
• Palliative care or home care patients
• Morbid obesity (BMI ≥40 kg/m²)
• History of neuromuscular disease
• Lower extremity amputation
• History of trauma affecting the thigh region
• Pregnancy

Sponsors & Collaborators

• Trabzon Kanuni Education and Research Hospital: lead

Study Sites (1)

Trabzon University Faculty of Medicine, Kanuni Training and Research Hospital, Trabzon, 61080

Trabzon, Trabzon, Turkey (Türkiye)

Location

Related Publications (3)

• Phongpreecha T, Ghanem M, Reiss JD, Oskotsky TT, Mataraso SJ, De Francesco D, Reincke SM, Espinosa C, Chung P, Ng T, Costello JM, Sequoia JA, Razdan S, Xie F, Berson E, Kim Y, Seong D, Szeto MY, Myers F, Gu H, Feister J, Verscaj CP, Rose LA, Sin LWY, Oskotsky B, Roger J, Shu CH, Shome S, Yang LK, Tan Y, Levitte S, Wong RJ, Gaudilliere B, Angst MS, Montine TJ, Kerner JA, Keller RL, Shaw GM, Sylvester KG, Fuerch J, Chock V, Gaskari S, Stevenson DK, Sirota M, Prince LS, Aghaeepour N. AI-guided precision parenteral nutrition for neonatal intensive care units. Nat Med. 2025 Jun;31(6):1882-1894. doi: 10.1038/s41591-025-03601-1. Epub 2025 Mar 25.

  PMID: 40133525 BACKGROUND

• Lopez-Gomez JJ, Sanchez-Lite I, Fernandez-Velasco P, Izaola-Jauregui O, Cebria A, Perez-Lopez P, Gonzalez-Gutierrez J, Estevez-Asensio L, Primo-Martin D, Gomez-Hoyos E, Jorge-Godoy E, De Luis-Roman DA. Artificial intelligence-assisted rectus femoris ultrasound vs. L3 computed tomography for sarcopenia assessment in oncology patients: establishing diagnostic cut-offs for muscle mass and quality. Front Nutr. 2025 Sep 25;12:1678989. doi: 10.3389/fnut.2025.1678989. eCollection 2025.

  PMID: 41080186 BACKGROUND

• Choi YH, Kim DH, Jeon ET, Lee HJ, Park TY, Yoon SH, Jin KN, Lee HW. Cluster analysis of thoracic muscle mass using artificial intelligence in severe pneumonia. Sci Rep. 2024 Jul 23;14(1):16912. doi: 10.1038/s41598-024-67625-2.

  PMID: 39043882 BACKGROUND

MeSH Terms

Conditions

Cerebral Hemorrhage; Subarachnoid Hemorrhage; Hematoma, Subdural; Hematoma, Epidural, Spinal; Ischemic Stroke; Brain Neoplasms; Sarcopenia

Condition Hierarchy (Ancestors)

Intracranial Hemorrhages; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Hemorrhage; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Intracranial Hemorrhage, Traumatic; Craniocerebral Trauma; Trauma, Nervous System; Hematoma; Wounds and Injuries; Stroke; Central Nervous System Neoplasms; Nervous System Neoplasms; Neoplasms by Site; Neoplasms; Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Atrophy; Pathological Conditions, Anatomical; Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 14, 2026
• First Posted: July 17, 2026
• Study Start: January 1, 2026
• Primary Completion: June 30, 2026
• Study Completion: June 30, 2026
• Last Updated: September 24, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)